Foghorn Therapeutics (FHTX) Liabilities and Shareholders Equity (2019 - 2026)

Foghorn Therapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $222.2 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 14.12% year-over-year to $222.2 million; the TTM figure through Mar 2026 stood at $851.5 million (down 27.82% YoY), while the FY2025 annual figure was $198.1 million, down 30.24% from the prior year.
• Liabilities and Shareholders Equity was $222.2 million for Q1 2026 at Foghorn Therapeutics, up from $198.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $488.3 million in Q1 2022 to a low of $198.1 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $316.6 million across 5 years, with a median of $308.4 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity jumped 133.21% in 2022, then sank 33.53% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $404.9 million in 2022, then fell by 29.38% to $285.9 million in 2023, then declined by 0.68% to $284.0 million in 2024, then sank by 30.24% to $198.1 million in 2025, then rose by 12.15% to $222.2 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $222.2 million (Q1 2026), $198.1 million (Q4 2025), and $205.0 million (Q3 2025), per Business Quant data.